RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

    NEXT STORY
    Predictive Genetic Testing & Consumer/Wellness Genomics: World Market Anticipated to Witness a CAGR of 13.9% Over 2019-2025
    PREV STORY
    Sharps Compliance Reports Fiscal 2019 Fourth Quarter Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer

    author_avatar
    NASDAQ Market News

    Biocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

    PRESS RELEASE: 9 January 2018, 07:01 CET   Biocartis and Amgen Sign New Companion Diagnostic ...

    author_avatar
    NASDAQ Market News

    Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma

    – The open-label trial will measure progression free survival of participants from date of ...

    author_avatar
    NASDAQ Market News